0001567619-19-009492.txt : 20190430
0001567619-19-009492.hdr.sgml : 20190430
20190430200905
ACCESSION NUMBER: 0001567619-19-009492
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190426
FILED AS OF DATE: 20190430
DATE AS OF CHANGE: 20190430
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 19784300
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2019-04-26
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
Common Stock
2019-04-26
4
M
0
3000
14.39
A
329211
D
Common Stock
2019-04-26
4
S
0
2000
82.4447
D
327211
D
Common Stock
2019-04-26
4
S
0
800
83.5875
D
326411
D
Common Stock
2019-04-26
4
S
0
200
84.405
D
326211
D
Common Stock
181341
I
Shares held by Jean-Jacques Bienaime Family Trust
Stock Option (Right to buy Common Stock)
14.39
2019-04-26
4
M
0
3000
0
D
2009-11-12
2019-05-11
Common Stock
3000
18000
D
Trade made pursuant to a 10b5-1 plan executed on November 15, 2018.
The price in column 4 is the weighted average price. The price actually received ranged from $82.085 to $83.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
The price in column 4 is the weighted average price. The price actually received ranged from $83.225 to $84.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Laura Randall Woodhead, Attorney-in-Fact
2019-04-30